ADVA timing card brings precise synchronization to open compute servers
9.11.2021 11:00:00 EET | Business Wire | Press release
ADVA (FSE: ADV) today launched its OSA 5400 TimeCard™, enabling operators of data center network infrastructure and 5G open RAN architectures to achieve highly accurate and reliable distribution and synchronization of time. Built on the OSA 5400 SyncModule™, ADVA’s new PCIe card brings sophisticated timing capabilities to any open compute server, transforming it into a precise and stable PTP grandmaster, boundary clock, slave clock or NTP server. The OSA 5400 TimeCard™ is the market’s first solution developed to the framework of the Open Compute Project’s (OCP) Time Appliance Project (TAP) and enhanced with both PTP and NTP functions. With advanced synchronization capabilities, it solves a key challenge for network operators as they virtualize their infrastructure and replace purpose-built hardware with standard servers.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211109005255/en/
ADVA’s OSA 5400 TimeCard™ is the industry’s first solution developed to the framework of the Open Compute Project’s Time Appliance Project. (Photo: Business Wire)
“Timing in data centers and other open compute cases like 5G open RAN is becoming increasingly crucial as a growing number of applications require new levels of performance. But the sub-microsecond synchronization needed for efficient resource sharing is something that open compute servers often cannot provide. Open compute customers need a way to inject the most advanced synchronization capabilities into their white box hardware. That’s why we’ve engineered our OSA 5400 TimeCard™. It brings our experience in network and application synchronization to open compute servers as well as open RAN equipment, enabling a whole new group of customers to benefit from our unique expertise,” said Gil Biran, general manager, Oscilloquartz, ADVA. “Our feature-rich OSA 5400 TimeCard™ meets and goes beyond OCP-TAP specifications. For data centers, finance and 5G infrastructure, it’s the key to bringing packet time distribution to the edge and access network.”
Developed specifically to OCP-TAP specifications, ADVA’s new OSA 5400 TimeCard™ is enhanced with an integrated GNSS receiver, PTP, NTP, PTP assurance, GNSS assurance and mitigation engines, as well as full sync management functionality. Easily plugged into a free PCIe slot of a standard open compute server or PC, it delivers extremely robust and precise synchronization. It offers a wide range of oscillator options to cost-effectively meet different levels of holdover requirements. Unlike competing solutions, the OSA 5400 TimeCard™ is designed for simplicity and assured operations. Its powerful control interface provides comprehensive device information as well as data on the performance of the timing network. The OSA 5400 TimeCard™ provides transparent assurance and can be managed by ADVA’s Ensemble Sync Director. Comprehensive visibility of the timing infrastructure puts operational teams in complete control, even with no specialist expertise in network synchronization.
“In a wide range of industries, the need is now being recognized for highly precise and stable synchronization of time and frequency across packet networks. But the race to roll our cost-effective standard hardware and embrace the advantages of server virtualization often leaves a timing gap. As strict synchronization is now vital for more and more applications, operators urgently need an efficient way to bring tight timing to open compute servers. Our OSA 5400 TimeCard™ is the answer,” commented Nir Laufer, VP, product line management, Oscilloquartz, ADVA. “Our PCIe pluggable card will empower data center operators, enterprises, utilities, broadcast networks, financial networks and 5G mobile service providers to harness time-sensitive applications through reliable, scalable and high-accuracy timing.”
Further details on the OSA 5400 TimeCard™ are available in these slides: https://adva.li/osa-5400-timecard-slides.
About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com.
About Oscilloquartz
Oscilloquartz is a pioneer in time and frequency synchronization. We design, manufacture and deploy end-to-end synchronization systems that ensure the delivery and assurance of highly precise timing information over next-generation packet and legacy networks. As an ADVA company, we’re creating new opportunities for tomorrow’s networks. For more information, please visit us at www.oscilloquartz.com.
Published by:
ADVA Optical Networking SE, Munich, Germany
www.adva.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211109005255/en/
Contact information
For press:
Gareth Spence
t +44 1904 699 358
public-relations@adva.com
For investors:
Stephan Rettenberger
t +49 89 890 665 854
investor-relations@adva.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Murata Launches Ultra-Low Power AMR Sensors to Boost Battery Life in Healthcare and Wearables Devices27.4.2026 05:00:00 EEST | Press release
Murata Manufacturing Co., Ltd. (TOKYO: 6981) (ISIN: JP3914400001) has commenced mass production of its MRMS166R and MRMS168R anisotropic magnetoresistance (AMR) sensors for healthcare, wearable, and IoT devices. The MRMS166R is the first AMR sensor to combine an average current consumption of 20 nA with operation from a 1.2 V supply, enabling extended battery life in coin cell-powered systems. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260413296947/en/ [Murata Manufacturing Co., Ltd.] AMR sensor The devices are solid-state magnetic sensors used for switching applications. They detect the presence or absence of a magnetic field and generate an output signal that system logic uses to control functions such as transitions between active and sleep modes. This enables contactless switching without mechanical components, improving reliability, and supporting sealed, miniaturized designs. Automatic switching between active and
Sun Pharma signs Definitive Agreement to Acquire Organon27.4.2026 02:51:00 EEST | Press release
Sun Pharmaceutical Industries Limited(Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) (together with its subsidiaries and/or associated companies, “Sun Pharma”) and Organon & Co. (NYSE: OGN) (“Organon”) today announced that they have entered into a definitive agreement under which Sun Pharma will acquire all outstanding shares of Organon for US$ 14.00 per share in an all‑cash transaction with an enterprise valuation of US$ 11.75 billion. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260426881370/en/ Organon is a global healthcare company formed through a spinoff from Merck, known as MSD outside of the United States and Canada, in 2021. Organon has a legacy of deep trust and strong brand equity among HCPs, patients, regulators and other stakeholders. A global leader in women’s health, the company’s portfolio includes more than 70 products across Women’s Health and General Medicines, which includes biosimila
PMC Organometallix Announces Price Increase on All Products25.4.2026 00:02:00 EEST | Press release
Due to significant changes in market conditions, PMC Organometallix, Inc. announces that effective May 1, 2026, or as contracts permit, prices across all product lines globally will increase by 10-25%. This adjustment is driven by sustained cost pressures from key inputs including rising raw material costs and escalating freight and logistics expenses. While the company has been absorbing these increases, the current economic environment brought on by the geopolitical crisis of the Iran conflict requires this adjustment to continue providing the high-quality, consistent materials and supply reliability that customers expect. PMC Organometallix will implement these changes in a transparent, collaborative manner and values your partnership while navigating these economic challenges. Customers with questions or to discuss a specific situation should contact their account representative. About PMC Group PMC Group is a growth-oriented, diversified, global chemicals and plastics company deli
Frankfurt Higher Regional Court upholds BESREMi ® arbitral award in favor of AOP Health24.4.2026 19:52:00 EEST | Press release
Today, the Higher Regional Court of Frankfurt upheld the February 20251 partial final ICC arbitral award in favor of AOP Orphan Pharmaceuticals GmbH (“AOP Health”) in its dispute with PharmaEssentia Corp. (“PharmaEssentia”). The ruling confirms the award which found the Taiwanese company to be liable for certain damages. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260424005227/en/ Portrait Dr. Rudolf Widmann, Founder AOP Health Credit: AOP Health/Daniel Ospelt Dr. Rudolf Widmann, one of the two founders of AOP Health, explains: “We very much welcome the Frankfurt Higher Regional Court’s decision that confirms our position. In the interest of our patients, we are dedicated to maintaining stable and sustainable access to BESREMi® and to responsibly navigating future challenges.” The Product in Dispute The conflict centers around BESREMi® (ropeginterferon alfa-2b), a product launched in 2019 and developed by AOP Health into
Compass Pathways Announces FDA Granted NDA Rolling Review Request and Awarded Commissioner's National Priority Voucher24.4.2026 17:37:00 EEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the U.S. Food and Drug Administration (FDA) granted Compass NDA rolling review request and selected COMP360, Compass’ proprietary formulation of synthetic psilocybin, for the Commissioner's National Priority Voucher (CNPV) program for treatment-resistant depression (TRD). Companies selected for the voucher program will be entitled to benefits including enhanced communications and a shortened 1-2 month review time following filing of a New Drug Application (NDA), while maintaining FDA’s rigorous safety and efficacy standards. “We are honored and grateful to be selected for the CNPV which is a clear validation of both the urgent unmet need facing millions of people living with treatment resistant depression and the innovative science of COMP360,” said Kabir Nath, Chief Executive Officer of Compass Pathways. “As the most advan
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
